OBIO vs TGT · rev $198.0K vs P/E 17, rev $51.98B
Orchestra BioMed Holdings Inc. (OBIO) versus Target Corporation (TGT) — a side-by-side from cached financials, not a winner call.
Orchestra BioMed Holdings Inc. (OBIO) is a biotechnology company listed on NASDAQ.
Target Corporation (TGT) is a discount stores company listed on NYSE. It is led by Michael J. Fiddelke.
Latest reported OBIO revenue for 2026-06-30 was $198.0K. Net income was -$44.4M. Revenue was up 80.0% from 2026-03-31 to 2026-06-30. OBIO currently screens at market cap $231.7M.
Latest reported TGT revenue for 2026-08-01 was $51.98B. Net income was $2.66B. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
OBIO currently screens at market cap $231.7M. TGT currently screens at market cap $58.05B and trailing P/E 16.9.
Not investment advice. Open the OBIO and TGT stock pages for the full models.
Not investment advice.